Establishment of a primary renal lymphoma model and its clinical relevance

Frontiers in Oncology

Oncology

Xiaoxi Li¹  Minyao Deng¹  Lingli Luo¹  Hui Qian¹  Chenxiao Zhang¹ 

[1] Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China;

关键词: primary renal lymphoma;    extranodal lymphoma;    extranodal dissemination;    MA-K;    MCD subtype;    LymphGen;    aggressive B-cell lymphoma;    translation pathway;   

DOI  :  10.3389/fonc.2023.1089187

 received in 2022-11-04, accepted in 2023-07-18,  发布年份 2023

来源: Frontiers

【 摘 要 】

Extranodal dissemination is an important feature of aggressive B-cell lymphoma. Owing to the lack of available animal models, the study on extranodal dissemination of lymphoma is greatly limited. Here, we identified a novel cell line, named MA-K, which originated from the Eμ-Myc;Cdkn2a−/− cell line, named MA-LN in this study. Compared to MA-LN, MA-K tended to disseminate in the kidney rather than the lymph nodes in the lymphoma transplantation model, resembling human primary renal lymphoma. The transcriptome analysis revealed that MA-K had undergone transcriptional evolution during the culture. The specialized transcriptional pattern analysis we proposed in this study identified that the FOXO1-BTG1-MYD88 pattern was formed in MA-K. Further analysis found that the translation pathway was the most enriched pathway in specially expressed genes (SEGs) in MA-K. Among the SEGs, three upregulated genes, RPLP2, RPS16, and MRPS16, and five downregulated genes, SSPN, CD52, ANKRD37, CCDC82, and VPREB3, in MA-K were identified as promising biomarkers to predict the clinical outcomes of human DLBCL. Moreover, the joint expression of the five-gene signature could effectively predict clinical outcomes of human DLBCL in three groups. These findings suggested that the MA-K cell line had strong clinical relevance with human aggressive B-cell lymphoma. Moreover, the MA-K primary renal lymphoma model, as a novel syngenetic mouse model, will be greatly useful for both basic research on lymphoma dissemination and preclinical efficacy evaluation of chemotherapy and immunotherapy.

【 授权许可】

Unknown   
Copyright © 2023 Li, Deng, Zhang, Luo and Qian